Starting today, millions of Medicare enrollees can fill prescriptions for popular GLP-1 weight-loss drugs at a flat $50 per month, a fraction of what these medications cost under standard Part D plans. The Centers for Medicare and Medicaid Services launched the Medicare GLP-1 Bridge on July 1, 2026, a short-term demonstration that runs through December 31, 2027. The program sidesteps the usual Part D cost-sharing structure entirely, removing the deductible barrier that has kept many older adults from starting or staying on treatment.
How the $50 copay bypasses Part D rules
The Bridge operates outside the Part D benefit, which means the $50 monthly copay does not trigger the Part D deductible and does not count toward a beneficiary’s true out-of-pocket costs, known as TrOOP. For enrollees who would otherwise face hundreds of dollars in cost-sharing before reaching catastrophic coverage, that distinction is significant. It effectively creates a parallel payment channel where the price is locked regardless of where a patient falls in the standard coverage phases.
Participating drug manufacturers supply eligible GLP-1 medications at a $245 net price per monthly supply, with the federal government covering the gap between that amount and the $50 patients pay at the pharmacy counter. Humana handles claims processing through its LI NET infrastructure, the same system already used for limited-income beneficiaries who temporarily lack Part D enrollment.
The covered products, when prescribed for weight management, include Wegovy injections and tablets, Zepbound KwikPen, and a newer entry called Foundayo. Certain Zepbound presentations are excluded, so patients and prescribers need to confirm which specific formulations qualify before filling a prescription. Pharmacies collect the $50 directly and submit claims to the central processor for adjudication and reimbursement.
Whether fixed copays will keep patients on treatment longer
The central question the Bridge is designed to answer is whether a predictable, low copay changes how long Medicare beneficiaries stay on GLP-1 therapy. Under standard Part D, cost-sharing can swing dramatically depending on a plan’s formulary tier, the coverage gap, and whether a patient qualifies for the Low Income Subsidy. Those unpredictable costs have historically driven high abandonment rates for expensive specialty drugs.
A flat $50 removes that variability. If the demonstration produces higher 12-month persistence rates among enrolled beneficiaries, especially dual-eligible individuals who cycle between Medicaid and Medicare coverage, it would give CMS concrete claims data to justify permanent coverage changes after the program expires at the end of 2027. The 18-month window is tight, but long enough to capture at least one full year of refill behavior for patients who start early.
Because the $50 copay sits outside TrOOP, patients who also take other Part D medications will not see their Bridge spending accelerate their path toward catastrophic coverage. That trade-off is worth understanding: the Bridge lowers the GLP-1 cost but does not help reduce out-of-pocket totals for other prescriptions.
